Home
report store
gastrointestinal stromal tumor gist epidemiology forecast

gastrointestinal-stromal-tumor-gist-epidemiology-forecast-report

Gastrointestinal Stromal Tumor (GIST) - Epidemiology Forecast - 2036

Published Date : 2025

Pages : 60

Region : United States, Japan, EU4 & UK

Summary
TOC Table of Content
LOT
- Sample Request

gastrointestinal stromal tumor gist epidemiology forecast

Gastrointestinal Stromal Tumor (GIST) Insights and Trends

GISTs can develop anywhere along the gastrointestinal tract, from the esophagus to the anus. The stomach accounts for approximately 55% of cases, making it the most common site of origin, followed by the duodenum and small intestine (30%). Less frequently, GISTs arise in the esophagus (5%), rectum (5%), and colon (2%). In rare cases, primary GISTs may develop outside the gastrointestinal tract, including the peritoneum, mesentery, omentum, liver, pancreas, ovaries, uterus, and prostate.
GISTs comprise less than 1% of all gastrointestinal tumors but are the most common mesenchymal tumors of the gastrointestinal tract.
GIST are classified by their risk of recurrence or progression rather than as benign or malignant. Risk assessment is based on tumor size, mitotic index, location, and mutation status. Molecular testing for Receptor Tyrosine Kinase (KIT) or Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) mutations is recommended, with SDH (succinate dehydrogenase) testing performed in tumors that are negative for both mutations.
GIST typically presents in the gastrointestinal tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation and survival of tumour cells. Around 12–15% of cases lack detectable mutations in both genes and are classified as KIT/PDGFRA wild-type (WT) GISTs. Additionally, <5% of GISTs are associated with hereditary or syndromic conditions, including neurofibromatosis type 1 (NF1), Carney triad syndrome, and other familial disorders.
GISTs can affect patients of all ages but are most predominant in older adults (median age, 65–69 years).
A substantial proportion of GIST patients present with advanced disease, with up to 50% exhibiting metastases or multifocal tumor involvement at diagnosis.

Gastrointestinal Stromal Tumor (GIST) Epidemiology Forecast in the 7MM

2025 Incident Cases of GIST: ~10,900
2036 Projected Incident Cases of GIST: ~XXX
GIST Growth Rate (2026–2036): ~2%

DelveInsight's ‘Gastrointestinal Stromal Tumor (GIST) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the GIST, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	North America : The US; Europe: Germany, France, Italy, and Spain and the UK; Asia-Pacific: Japan
GIST Epidemiology CAGR (Forecast period)	~2% (2026–2036)
GIST Epidemiology Segmentation Analysis	Patient Burden Assessment Total Incident Cases of GIST Age-specific Incident Cases of GIST Stage-specific Incident Cases of GIST Gender-specific Incident Cases of GIST Mutation-specific Incident Cases of GIST Treated Cases of GIST

Gastrointestinal Stromal Tumor (GIST) Understanding

Gastrointestinal Stromal Tumor (GIST) Overview

GIST is a rare type of mesenchymal tumor of the gastrointestinal tract, most commonly arising in the stomach or small intestine. It is primarily driven by activating mutations in the KIT or PDGFRA genes, which lead to uncontrolled cell growth. Despite its rarity, reported incidence has increased in recent years due to improved diagnostic techniques and wider use of molecular testing.

Further details are provided in the report.

Gastrointestinal Stromal Tumor (GIST) Diagnosis

Diagnosis typically involves a combination of imaging, histopathology, and molecular testing. Techniques such as CT scans and endoscopy help identify tumor location and size, while biopsy confirms the diagnosis. Immunohistochemical markers like KIT (CD117) and DOG1 are commonly used to distinguish GIST from other tumors. Genetic testing is essential to identify KIT or PDGFRA mutations, as this directly guides treatment decisions and therapy selection.

Further details are provided in the report.

Gastrointestinal Stromal Tumor (GIST) Epidemiology

Key Findings from GIST Epidemiological Analysis and Forecast

In 2025, the US accounted for the highest incident cases of GIST with more than 5,600 cases. These cases are anticipated to increase during the forecast period.
The number of new cases of GISTs in the United States each year has been estimated at 5,000–6,000.
GISTs constitute 0.1–3% of all GI neoplasms. The estimated annual incidence is 10–15 new cases per million people or approximately 3,000–5,000 new cases in the US yearly. Although GISTs may occur at all ages, the peak incidence is in the sixth decade of life, with a slight male predominance.
In the United States, GISTs most commonly arise in the stomach (~60%) and small intestine (~35%), while a smaller proportion occur in the esophagus, colon, rectum, or, rarely, outside the gastrointestinal tract within the abdominal cavity.
GIST is more common among males than females.
GIST is more commonly diagnosed at the localized stage compared to other stages.

Scope of the Report

The report covers a segment of a descriptive overview of GIST, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Gastrointestinal Stromal Tumor (GIST) Patient Population Forecast

Report Key Strengths

Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

FAQs

What are the disease risks, burdens, and unmet needs of GIST? What will be the growth opportunities across the 7MM concerning the patient population with GIST?
What is the historical and forecasted GIST patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Epidemiology Methodology of Gastrointestinal Stromal Tumor (GIST)

5 Gastrointestinal Stromal Tumor (GIST) Epidemiology Overview at a Glance

5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM

5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM

6 Disease Background And Overview of Gastrointestinal Stromal Tumor (GIST)

6.1 Introduction

6.2 Causes

6.3 Signs And Symptoms

6.4 Diagnosis

6.4.1 Differential Diagnosis

6.4.2 Diagnostic Algorithm

6.4.3 Diagnostic Guidelines

7 Epidemiology and Patient Population of Gastrointestinal Stromal Tumor (GIST)

7.1 Key Findings

7.2 Assumption and Rationale

7.3 Total Prevalent Cases of Gastrointestinal Stromal Tumor (GIST) in the 7MM

7.4 The United States

7.4.1 Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.4.3 Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.4.4 Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.4.4 Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.4.5 Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.4.6 Treated Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.5 EU4 and the UK

7.5.1 Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK

7.5.2 Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK

7.5.3 Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK

7.5.4 Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK

7.5.5 Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in EU4 and the UK

7.5.6 Treated Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.6 Japan

7.6.1 Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan

7.6.2 Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan

7.6.3 Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan

7.6.4 Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan

7.6.5 Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST) in Japan

7.6.6 Treated Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

8 Patient Jounery of Gastrointestinal Stromal Tumor (GIST)

9 KOL Views of Gastrointestinal Stromal Tumor (GIST)

10 Appendix

10.1 Bibliography

10.2 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of Gastrointestinal Stromal Tumor Epidemiology (2021-2034)

Table 2: Key Events

Table 3: Diagnosis of GIST

Table 4: Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM (2021-2034)

Table 5: Total Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Table 6: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Table 7: Age-specific Incident of Gastrointestinal Stromal Tumor in the US (2021-2034)

Table 8: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Table 9: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Table 10: Total Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Table 11: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Table 12: Age-specific Incident of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Table 13: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Table 14: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Table 15: Total Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Table 16: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Table 17: Age-specific Incident of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Table 18: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Table 19: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Table 20: Total Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Table 21: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Table 22: Age-specific Incident of Gastrointestinal Stromal Tumor in France (2021-2034)

Table 23: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Table 24: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Table 25: Total Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Table 26: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Table 27: Age-specific Incident of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Table 28: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Table 29: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Table 30: Total Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Table 31: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Table 32: Age-specific Incident of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Table 33: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Table 34: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Table 35: Total Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Table 36: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Table 37: Age-specific Incident of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Table 38: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Table 39: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Table 40: Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Table 41: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Table 42: Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Table 43: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Table 44: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

List of Figures:

List of Figures

Figure 1: Signs and Symptoms of Gastrointestinal Stromal Tumor (GIST)

Figure 2: Primary GIST Anatomic Locations and Relative Frequencies

Figure 3: Classification of Gastrointestinal Stromal Tumor (GIST)

Figure 4: The Structure of the KIT Receptor Tyrosine Kinase

Figure 5: KIT Gain-of-function Mutations in GISTs

Figure 6: KIT and PDGFRA Cell Signaling Pathways

Figure 7: KIT and PDGFRA Receptor Tyrosine Kinases with Location and Relative Frequencies of Mutations

Figure 8: Genetic and Cytogenetic changes Associated with Progression of Gastrointestinal Stromal Tumor

Figure 9: Total Incident Cases of Gastrointestinal Stromal Tumor in the 7MM (2021-2034)

Figure 10: Total Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Figure 11: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Figure 12: Age-specific Incident of Gastrointestinal Stromal Tumor in the US (2021-2034)

Figure 13: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Figure 14: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the US (2021-2034)

Figure 15: Total Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Figure 16: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Figure 17: Age-specific Incident of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Figure 18: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Figure 19: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the EU-5 (2021-2034)

Figure 20: Total Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Figure 21: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Figure 22: Age-specific Incident of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Figure 23: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Figure 24: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Germany (2021-2034)

Figure 25: Total Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Figure 26: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Figure 27: Age-specific Incident of Gastrointestinal Stromal Tumor in France (2021-2034)

Figure 28: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Figure 29: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in France (2021-2034)

Figure 30: Total Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Figure 31: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Figure 32: Age-specific Incident of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Figure 33: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Figure 34: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Italy (2021-2034)

Figure 35: Total Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Figure 36: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Figure 37: Age-specific Incident of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Figure 38: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Figure 39: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Spain (2021-2034)

Figure 40: Total Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Figure 41: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Figure 42: Age-specific Incident of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Figure 43: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Figure 44: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in the UK (2021-2034)

Figure 45: Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Figure 46: Gender-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Figure 47: Age-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Figure 48: Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Figure 49: Stage-specific Incident Cases of Gastrointestinal Stromal Tumor in Japan (2021-2034)

Related Reports

Gastrointestinal Stromal Tumor (GIST) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2026

Gastrointestinal Stromal Tumor (GIST) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2026 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Gastrointestinal Stromal Tumor (GIST).

Gastrointestinal Stromal Tumor (GIST) - Pipeline Insight, 2026

Gastrointestinal Stromal Tumor (GIST) Pipeline Insights, 2026 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the..

License Type

Offer